Home › Therapeutic areas › Oncology › Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia (3 companies)

Companies with an active program in Waldenstrom Macroglobulinemia.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13